Living the PCSK9 Adventure: from the Identification of a New Gene in Familial Hypercholesterolemia Towards a Potential New Class of Anticholesterol Drugs
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Living the PCSK9 Adventure: from the Identification of a New Gene in Familial Hypercholesterolemia Towards a Potential New Class of Anticholesterol Drugs
Authors
Keywords
Hypercholesterolemia, LDLR, PCSK9, Gain of function mutations, Loss of function, Evolocumab, Alirocumab
Journal
Current Atherosclerosis Reports
Volume 16, Issue 9, Pages -
Publisher
Springer Nature
Online
2014-07-22
DOI
10.1007/s11883-014-0439-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Proprotein Convertase Subtilisin/Kexin Type 9 Deficiency Reduces Melanoma Metastasis in Liver
- (2015) Xiaowei Sun et al. NEOPLASIA
- Effects of RG7652, a fully human mAb against proprotein convertase subtilisin/kexin type 9, on LDL-c: a Phase I, randomised, double-blind, placebo-controlled, single- and multiple-dose study
- (2014) W. Tingley et al. EUROPEAN HEART JOURNAL
- Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance
- (2014) Erik Stroes et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Anti-PCSK9 Monotherapy for Hypercholesterolemia
- (2014) Michael J. Koren et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- =EFFICACY AND SAFETY OF BOCOCIZUMAB (RN316/PF-04950615), A MONOCLONAL ANTIBODY AGAINST PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 IN STATIN-TREATED HYPERCHOLESTEROLEMIC SUBJECTS: RESULTS FROM A RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY (NCT: 01592240)
- (2014) Christie M. Ballantyne et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
- (2014) Dirk J. Blom et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia
- (2013) Evan A. Stein et al. CIRCULATION
- Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia
- (2013) Michael J. Koren et al. CIRCULATION
- Characterization of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Trafficking Reveals a Novel Lysosomal Targeting Mechanism via Amyloid Precursor-like Protein 2 (APLP2)
- (2013) Rachel M. DeVay et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
- (2013) Kevin Fitzgerald et al. LANCET
- Association of serum proprotein convertase subtilisin/kexin type 9 with carotid intima media thickness in hypertensive subjects
- (2013) Chan Joo Lee et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- 1-Year results from OSLER trial of anti-PCSK9 monoclonal antibody evolocumab
- (2013) Bryony M. Mearns Nature Reviews Cardiology
- Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia
- (2013) M.C.G.J. Brouwers et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial
- (2012) Helena Bjermo et al. AMERICAN JOURNAL OF CLINICAL NUTRITION
- Plasma Lipoprotein-associated Phospholipase A2 Is Inversely Correlated with Proprotein Convertase Subtilisin-kexin Type 9
- (2012) Alexander Constantinides et al. ARCHIVES OF MEDICAL RESEARCH
- Proprotein Convertase Subtilisin/Kexin Type 9 Interacts With Apolipoprotein B and Prevents Its Intracellular Degradation, Irrespective of the Low-Density Lipoprotein Receptor
- (2012) Hua Sun et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Common and Low-Frequency Genetic Variants in the PCSK9 Locus Influence Circulating PCSK9 Levels
- (2012) Ekaterina Chernogubova et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia
- (2012) Marianne Abifadel et al. ATHEROSCLEROSIS
- Proprotein convertase subtilisin–kexin type 9 is elevated in proteinuric subjects: Relationship with lipoprotein response to antiproteinuric treatment
- (2012) Arjan J. Kwakernaak et al. ATHEROSCLEROSIS
- Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia
- (2012) Frederick Raal et al. CIRCULATION
- Relationship of proprotein convertase subtilisin-kexin type 9 levels with resistin in lean and obese subjects
- (2012) Arjan J. Kwakernaak et al. CLINICAL BIOCHEMISTRY
- Design and Rationale of the LAPLACE-TIMI 57 Trial: A Phase II, Double-Blind, Placebo-Controlled Study of the Efficacy and Tolerability of a Monoclonal Antibody Inhibitor of PCSK9 in Subjects With Hypercholesterolemia on Background Statin Therapy
- (2012) Payal Kohli et al. CLINICAL CARDIOLOGY
- Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients
- (2012) David Sullivan et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Regulation of Epithelial Sodium Channel Trafficking by Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
- (2012) Vikas Sharotri et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia
- (2012) R. Huijgen et al. JOURNAL OF LIPID RESEARCH
- PCSK9 SNP rs11591147 is associated with low cholesterol levels but not with cognitive performance or noncardiovascular clinical events in an elderly population
- (2012) Iris Postmus et al. JOURNAL OF LIPID RESEARCH
- Effects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels
- (2012) Clapton S. Dias et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy
- (2012) James M. McKenney et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Discovery of a New Role of Human Resistin in Hepatocyte Low-Density Lipoprotein Receptor Suppression Mediated in Part by Proprotein Convertase Subtilisin/Kexin Type 9
- (2012) Michelle Melone et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study
- (2012) Michael J Koren et al. LANCET
- Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study
- (2012) Robert P Giugliano et al. LANCET
- PCSK9 antibody reduces LDL cholesterol
- (2012) Sarah Crunkhorn NATURE REVIEWS DRUG DISCOVERY
- Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
- (2012) Evan A. Stein et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia
- (2012) Eli M. Roth et al. NEW ENGLAND JOURNAL OF MEDICINE
- Annexin A2 Is a Natural Extrahepatic Inhibitor of the PCSK9-Induced LDL Receptor Degradation
- (2012) Nabil G. Seidah et al. PLoS One
- Circulating Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Regulates VLDLR Protein and Triglyceride Accumulation in Visceral Adipose Tissue
- (2011) Anna Roubtsova et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Endogenous Estrogens Lower Plasma PCSK9 and LDL Cholesterol But Not Lp(a) or Bile Acid Synthesis in Women
- (2011) Lena Persson et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: Results from a crossover study
- (2011) Tohru Noguchi et al. ATHEROSCLEROSIS
- Effect of the Mediterranean diet with and without weight loss on surrogate markers of cholesterol homeostasis in men with the metabolic syndrome
- (2011) Caroline Richard et al. BRITISH JOURNAL OF NUTRITION
- Novel Loss-of-Function PCSK9 Variant Is Associated with Low Plasma LDL Cholesterol in a French-Canadian Family and with Impaired Processing and Secretion in Cell Culture
- (2011) J. Mayne et al. CLINICAL CHEMISTRY
- PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke
- (2011) Estelle Rousselet et al. JOURNAL OF LIPID RESEARCH
- Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents
- (2011) Robert J Konrad et al. Lipids in Health and Disease
- Increased Secretion of Lipoproteins in Transgenic Mice Expressing Human D374Y PCSK9 Under Physiological Genetic Control
- (2010) Bronwen Herbert et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients
- (2010) Bertrand Cariou et al. ATHEROSCLEROSIS
- Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents
- (2010) Marianne Abifadel et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain
- (2010) Mali Liu et al. JOURNAL OF LIPID RESEARCH
- Effects of PCSK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian population
- (2010) Ilaria Guella et al. JOURNAL OF LIPID RESEARCH
- PCSK9R46L, Low-Density Lipoprotein Cholesterol Levels, and Risk of Ischemic Heart Disease
- (2010) Marianne Benn et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- PCSK9 Dominant Negative Mutant Results in Increased LDL Catabolic Rate and Familial Hypobetalipoproteinemia
- (2009) Bertrand Cariou et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles
- (2009) Giuseppe Danilo Norata et al. ATHEROSCLEROSIS
- Longitudinal Association of PCSK9 Sequence Variations With Low-Density Lipoprotein Cholesterol Levels
- (2009) Chiang-Ching Huang et al. Circulation-Cardiovascular Genetics
- Healthy Individuals Carrying the PCSK9 p.R46L Variant and Familial Hypercholesterolemia Patients Carrying PCSK9 p.D374Y Exhibit Lower Plasma Concentrations of PCSK9
- (2009) S. E. Humphries et al. CLINICAL CHEMISTRY
- PCSK9 impedes hepatitis C virus infectionin vitroand modulates liver CD81 expression
- (2009) Patrick Labonté et al. HEPATOLOGY
- The molecular basis of familial hypercholesterolemia in Lebanon: Spectrum ofLDLRmutations and role ofPCSK9as a modifier gene
- (2009) Marianne Abifadel et al. HUMAN MUTATION
- Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease
- (2009) Marianne Abifadel et al. HUMAN MUTATION
- Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation
- (2009) Steve Poirier et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Genetic and Metabolic Determinants of Plasma PCSK9 Levels
- (2009) Susan G. Lakoski et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels
- (2009) Jason S. Troutt et al. JOURNAL OF LIPID RESEARCH
- A new method for measurement of total plasma PCSK9: clinical applications
- (2009) Geneviève Dubuc et al. JOURNAL OF LIPID RESEARCH
- Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants
- (2009) Sekar Kathiresan et al. NATURE GENETICS
- Inhibition of PCSK9: A powerful weapon for achieving ideal LDL cholesterol levels
- (2009) D. Steinberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population
- (2008) Eliana Polisecki et al. ATHEROSCLEROSIS
- Variation in PCSK9, low LDL cholesterol, and risk of peripheral arterial disease
- (2008) Aaron R. Folsom et al. ATHEROSCLEROSIS
- Plasma PCSK9 Concentrations Correlate with LDL and Total Cholesterol in Diabetic Patients and Are Decreased by Fenofibrate Treatment
- (2008) G. Lambert et al. CLINICAL CHEMISTRY
- PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1
- (2008) Mary Cabell Jonas et al. EMBO REPORTS
- Importance of Proprotein Convertase Subtilisin/Kexin Type 9 in the Hormonal and Dietary Regulation of Rat Liver Low-Density Lipoprotein Receptors
- (2008) Lena Persson et al. ENDOCRINOLOGY
- Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes
- (2008) Cédric Langhi et al. FEBS LETTERS
- Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration
- (2008) Ahmed Zaid et al. HEPATOLOGY
- Dual Mechanisms for the Fibrate-mediated Repression of Proprotein Convertase Subtilisin/Kexin Type 9
- (2008) Sanae Kourimate et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Characterization of novel mutations in the catalytic domain of the PCSK9 gene
- (2008) J. Cameron et al. JOURNAL OF INTERNAL MEDICINE
- APCSK9Missense Variant Associated with a Reduced Risk of Early-Onset Myocardial Infarction
- (2008) Sekar Kathiresan NEW ENGLAND JOURNAL OF MEDICINE
- Molecular basis for LDL receptor recognition by PCSK9
- (2008) H. J. Kwon et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
- (2008) M. Frank-Kamenetsky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Familial hypercholesterolaemia in Portugal
- (2007) M. Bourbon et al. ATHEROSCLEROSIS
- Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa
- (2007) Vivienne M. Homer et al. ATHEROSCLEROSIS
- Genetic variants in PCSK9 in the Japanese population: Rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population
- (2007) Yasuko Miyake et al. ATHEROSCLEROSIS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search